Orlistat is a well‑known weight‑loss drug that also blocks a key enzyme cancer cells use to make fats, and researchers have been trying to re‑use it against tumors for years. Recently a team developed a new way to deliver orlistat directly into prostate cancer cells by packing it inside tiny, engineered particles called Cys8E nanoparticles […]
A new, promising concept was explored for men with metastatic castration‑resistant prostate cancer: PSMA‑targeted CAR‑NK cells engineered to be an off‑the‑shelf immunotherapy that aims to combine targeted tumor killing with a safer toxicity profile. The work, presented at AUA 2026 meeting, comes from investigators affiliated with the Cancer Hospital, Chinese Academy of Medical Sciences, who […]
177Lu-D-Dan-Phe-PSMA, also called 177Lu-LNC1011, represents a next-generation PSMA-targeted radioligand therapy designed to improve on existing options like Pluvicto for metastatic castration-resistant prostate cancer (mCRPC). Unlike Pluvicto, which clears rapidly through the kidneys and limits sustained tumor exposure, this agent incorporates a dansyl modification for prolonged intratumoral retention while preserving systemic clearance. Early phase 1 results […]
Researchers at Roswell Park Comprehensive Cancer Center have identified a critical vulnerability in how prostate cancers escape standard hormonal therapy. The study reveals that when androgen receptor signaling is suppressed by ADT or AR pathway inhibitors, cancer cells compensate by ramping up BCL-2, an anti-apoptotic protein that helps them survive treatment. The findings suggest that […]
OncoACP3‑DOTA is a small‑molecule ligand directed at prostatic acid phosphatase (ACP3, also historically called PAP), a membrane‑bound phosphatase that is highly specific to the prostate, with only weak expression in normal tissues such as kidney. Preclinical work showed that ACP3 is retained in many prostate tumors, including lesions with low or absent PSMA expression, and […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! This week’s newsletter is a bit lighter than usual, partly because it’s becoming increasingly difficult to find detailed information on new clinical trials. The trials are there, but the mechanisms behind the proposed drugs are often hard to identify. […]
A new CRISPR system recently published in Nature could change how we think about selectively eliminating cancer cells without touching healthy tissue. Instead of using the classic Cas9 to edit DNA, researchers have repurposed Cas12a2, an enzyme that first binds to a specific RNA sequence and then unleashes a wave of DNA destruction across the […]
Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses. A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the […]
A huge international team has just completed the largest study ever on how our genes control the levels of proteins circulating in our blood. The work, led by researchers at Queen Mary University of London and the Berlin Institute of Health, brings together data from more than 78,000 people across 38 cohorts worldwide and has […]
Radioligand therapy transformed advanced prostate cancer care with PSMA targeting. Now experts eye options for PSMA-resistant or low-expression cases. At APCCC 2026, Dr. Ken Herrmann named ACP3, B7-H3, and STEAP1/STEAP2 as top priorities. These could reach patients (outside clinical trials) in four to five years. ACP3, or prostatic acid phosphatase, binds tighter than PSMA in […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy